ArticleUnited European gastroenterology journal2017
Antibiotic resistance and
Article in United European gastroenterology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Evidence-based clinical practice guidelines for peptic ulcer disease 2026.Journal of gastroenterology · 2026Guideline
- Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition.Journal of gastroenterology · 2026Guideline
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Pooled it
- Helicobacter pylori Management in Older Adults: Current Perspectives From Japan.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Third-Line and Later Susceptibility-GuidedJournal of clinical medicine · 2026Article
- A Review on the Progress and Strategies ofGastroenterology research and practice · 2026Review
- TargetingJournal of clinical biochemistry and nutrition · 2025Article
- Clinical Effectiveness of Penicillin-Free Therapies in First-Line and Rescue Treatments forAntibiotics (Basel, Switzerland) · 2025Review
- Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy afterAnnals of medicine · 2022Article
- Treatment ofWorld journal of gastroenterology · 2021Review
- Therapeutic Potential of Sitafloxacin as a New Drug Candidate forAntibiotics (Basel, Switzerland) · 2021Article
- Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.Nature reviews. Gastroenterology & hepatology · 2021Review
- Sitafloxacin for Third-LineJournal of clinical medicine · 2021Review
- Optimization Strategies Aimed to Increase the Efficacy ofMolecules (Basel, Switzerland) · 2020Review
- Effective therapeutic regimens in two South Asian countries with high resistance to majorAntimicrobial resistance and infection control · 2019Article
- Reply to the letter to the editor: H. pylori test-and-treat should not be put off for gastric cancer prevention in East Asia any longer.Journal of gastroenterology · 2018Article
- Acquisition of double mutation inUnited European gastroenterology journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aim
methodsPenicillin-allergic patients infected with
resultsFifty-seven patients were analyzed, and the overall eradication rate was 89.5%. The eradication rate in cases of double antibiotic resistance to metronidazole and sitafloxacin was 40.0%, whereas for other combinations of resistance, this was above 90.0%. Finally, the eradication rate of
conclusionTen days of sitafloxacin and metronidazole triple therapy was safe and highly effective in eradicating
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.